معرفی
Hirsh Koyi is a Researcher affiliated with Uppsala University through the Centre for Research & Development at Region Gävleborg, focusing on clinical oncology and respiratory medicine. His work bridges hospital-based clinical research with academic investigation, primarily conducted at Gävle Hospital.
His research spans lung cancer diagnostics, pleural effusion analysis, pharmacogenomics of chemotherapy toxicity, and swallowing dysfunction in respiratory diseases. Key interests include:
- Non-small cell lung cancer molecular subtyping and prognostic biomarkers
- Genetic variants influencing gemcitabine/carboplatin toxicity
- Dysphagia mechanisms in COPD and post-COVID recovery
- Ethnic disparities in mesothelioma and lung cancer outcomes
Recent publications demonstrate consistent focus on translational oncology, with trends toward personalized treatment prediction using gene expression and pharmacogenomic markers. His collaborative work frequently addresses real-world clinical challenges in elderly cancer patients and post-ICU rehabilitation.
Koyi maintains active clinical research collaborations across Swedish medical centers, particularly in pharmacokinetic studies and respiratory complication management. His work appears in journals spanning oncology, respiratory medicine, and analytical pharmacology.
